Rubella prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP).
These revised Immunization Practices Advisory Committee (ACIP) recommendations for the prevention of rubella update the previous recommendations (MMWR 1984;33:301-10,315-8) to include implementation of a new two-dose schedule for measles-mumps-rubella (MMR) vaccine. Current information about vaccine effectiveness, duration of immunity, vaccination in pregnancy, and progress in controlling congenital rubella syndrome (CRS) is also included.
D002487:Centers for Disease Control and Prevention, U.S.; D000075202:Contraindications; D004196:Disease Outbreaks / Q000517:prevention & control; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007223:Infant; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D011159:Population Surveillance; D011247:Pregnancy; D012409:Rubella / Q000151:congenital / Q000517:prevention & control*; D012411:Rubella Vaccine / Q000008:administration & dosage / Q000009:adverse effects; D013577:Syndrome; D014481:United States; D014611:Vaccination / Q000379:methods
D004338:Drug Combinations; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine